ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Recipharm acquires Sanofi’s inhalation assets

by Rick Mullin
June 23, 2018 | APPEARED IN VOLUME 96, ISSUE 26

Recipharm, a Swedish drug services firm, will pay $59 million to acquire Sanofi’s inhalation drug business in Holmes Chapel, England. It will get a 125,000-m2 facility that specializes in metered dose inhalers and nasal sprays with development areas for dry-powder inhalation technology; the site will supplement Recipharm’s Morrisville, N.C., inhalation facility. Sanofi has signed a long-term supply agreement with Recipharm. The Holmes Chapel business, with annual revenues of about $67 million, currently manufactures Vectra Group’s Flutiform asthma inhaler.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment